Home > Annual Financials > PIRAMAL PHARMA

PIRAMAL PHARMA Financial Statement Analysis
[BOM: 543635|NSE : PPLPHARMA]

The Revenues of PIRAMAL PHARMA have increased by 15.39% YoY .
The Earnings Per Share (EPS) of PIRAMAL PHARMA has increased by Positive YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

PIRAMAL PHARMA Last 5 Annual Financial Results
[BOM: 543635|NSE : PPLPHARMA]

ConsolidatedMar2024
Mar2023
Mar2022
Mar2021
Revenues ₹8,171 Cr₹7,082 Cr₹6,559 Cr₹6,315 Cr
Expenses ₹7,001 Cr₹6,453 Cr₹5,609 Cr₹4,887 Cr
Operating Profit (Excl OI) ₹1,171 Cr₹628 Cr₹950 Cr₹1,428 Cr
Other Income ₹201 Cr₹225 Cr₹276 Cr₹164 Cr
Interest ₹448 Cr₹344 Cr₹198 Cr₹163 Cr
Depreciation ₹741 Cr₹677 Cr₹586 Cr₹545 Cr
Profit Before Tax ₹179 Cr₹-120 Cr₹485 Cr₹949 Cr
Profit After Tax ₹18 Cr₹-186 Cr₹376 Cr₹835 Cr
Consolidated Net Profit ₹18 Cr₹-186 Cr₹376 Cr₹835 Cr
Earnings Per Share (Rs)₹0.13₹-1.56₹3.17₹8.40
PAT Margin (%)0.19-2.305.1511.92
ROE(%)0.24-2.776.1114.90
ROCE(%)5.071.957.1013.06
Total Debt/Equity(x)0.580.810.600.52

Key Financials

Market Cap : ₹ 28,039.5 Cr
Revenue (TTM) : ₹ 9,151.2 Cr
Net Profit(TTM) : ₹ 18.2 Cr
EPS (TTM) : ₹ 0.1
P/E (TTM) : 1,540.6

Industry Peers & Returns1W1M1Y
PIRAMAL PHARMA 3.6% 1.5% 42.7%
SUN PHARMACEUTICAL INDUSTRIES 1.6% -2.9% 17.2%
DIVIS LABORATORIES 1.5% 10.4% 51.9%
CIPLA 2.3% 1.9% 2.8%
TORRENT PHARMACEUTICALS 1.4% 1.3% 17%
DR REDDYS LABORATORIES 5.7% 14.1% 15.2%
MANKIND PHARMA 0.2% -2.4% 12.5%
ZYDUS LIFESCIENCES 5.1% 10.9% -4.4%
LUPIN 2% -2.2% 27.9%


PIRAMAL PHARMA Revenues
[BOM: 543635|NSE : PPLPHARMA]

Y-o-Y

15.39 %

5 Yr CAGR

8.97 %

Years Revenues % Change
Mar2024 ₹8,171 Cr
15.39
Mar2023 ₹7,082 Cr
7.97
Mar2022 ₹6,559 Cr
3.87
Mar2021 ₹6,315 Cr -


PIRAMAL PHARMA Operating Profit
[BOM: 543635|NSE : PPLPHARMA]

Y-o-Y

86.32 %

5 Yr CAGR

-6.41 %

Years Operating Profit % Change
Mar2024 ₹1,171 Cr
86.32
Mar2023 ₹628 Cr
-33.85
Mar2022 ₹950 Cr
-33.50
Mar2021 ₹1,428 Cr -

Operating Margins
Y-o-Y

61.44 %

5 Yr CAGR

-14.12 %

Years Operating Margin% % Change
Mar2024 14.32%
61.44
Mar2023 8.87%
-38.74
Mar2022 14.48%
-35.96
Mar2021 22.61% -

PIRAMAL PHARMA Profit After Tax
[BOM: 543635|NSE : PPLPHARMA]

Y-o-Y

Positive

5 Yr CAGR

-72.26 %

Years Profit After Tax % Change
Mar2024 ₹18 Cr
Positive
Mar2023 ₹-186 Cr
Negative
Mar2022 ₹376 Cr
-54.98
Mar2021 ₹835 Cr -

PAT Margins
Y-o-Y

Positive

5 Yr CAGR

-74.83 %

Years PAT Margin(%) % Change
Mar2024 0.19 %
Positive
Mar2023 -2.3 %
Negative
Mar2022 5.15 %
-56.80
Mar2021 11.92 % -

PIRAMAL PHARMA Earnings Per Share (EPS)
[BOM: 543635|NSE : PPLPHARMA]

Y-o-Y

Positive

5 Yr CAGR

-75.08 %

Years EPS % Change
Mar2024 ₹0.13
Positive
Mar2023 ₹-1.56
Negative
Mar2022 ₹3.17
-62.26
Mar2021 ₹8.40 -

PIRAMAL PHARMA Return on Capital Employed (ROCE)
[BOM: 543635|NSE : PPLPHARMA]

Y-o-Y

160.00 %

5 Yr CAGR

-27.05 %

Years ROCE % Change
Mar2024 5.07%
160.00
Mar2023 1.95%
-72.54
Mar2022 7.1%
-45.64
Mar2021 13.06% -

PIRAMAL PHARMA Share Price vs Sensex

Current Share Price : ₹211.0
Current MarketCap: ₹ 28,039.5 Cr
Updated EOD on :Jun 09,2025

Share Price Returns(%) 1 Week 1 Month 1 Year
PIRAMAL PHARMA

3.6%

1.5%

42.7%

SENSEX

1.3%

2.6%

7.8%

PIRAMAL PHARMA related INDICES

BSE Indices1W1M1Y
BSE ALLCAP 6.4% 8.9% 7.5%
BSE MIDSMALLCAP 4.7% 9% 8.4%
BSE 500 SHARIAH 4.3% 4.3% 1.1%
BSE SMALLCAP SELECT INDEX 4.1% 15.7% 11.9%
BSE 250 SMALLCAP INDEX 3.2% 14.7% 9.1%
NSE Indices1W1M1Y
NIFTY SMALLCAP 50 4.9% 16.8% 15.5%
NIFTY SMALLCAP 100 4.3% 16.6% 10.4%
NIFTY500 MOMENTUM 50 4.3% 11% NA
NIFTY ALPHA 50 3.9% 14.6% -4%
NIFTY SMALLCAP 250 3.3% 15.4% 9.8%

You may also like the below Video Courses


FAQ about PIRAMAL PHARMA Financials


How the annual revenues of PIRAMAL PHARMA have changed ?

The Revenues of PIRAMAL PHARMA have increased by 15.39% YoY .

How the Earnings per Share (EPS) of PIRAMAL PHARMA have changed?

The Earnings Per Share (EPS) of PIRAMAL PHARMA has increased by Positive YoY .